Sarepta's next DMD drug seems to get the job done, but Elevidys casts long shadow

Sarepta Therapeutics' next Duchenne muscular dystrophy med seems to be doing the job of spurring dystrophin expression. But does any of the data for SRP-5051 matter given the recent approval of the biotech’s gene therapy for the same condition, Elevidys?